arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA
$39.04 ▼ -0.45 (-1.15%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Bullish
auto_awesome

Analytical Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $44.7B
Dividend Yield —
Revenue Growth 4.3% ↘
Op. Margin 12.5% ↗
ROIC 21.5% ↗
FCF / Share $1.44 ↗
Trailing P/E 31.7x
Price / Book 5.7x
FCF Yield 3.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.26B
↑ +4.3% —
Net Income Profit after all expenses
$1.41B
↑ +186.0% —
Operating Margin Operating profit as % of sales
12.5%
↑ +782.4% 62th
FCF / Share Free cash flow per share
$1.44
↑ +30.6% —
Long-Term Debt Long-term obligations
$14.14B
↑ +24.1% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
60
Returns ↑
84
Financial Health ↑
62
Cash Quality ↑
72

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 45 quarters